German drug group Bayer said Monday that it had halted trials of its leading cancer treatment Nexavar for one of the main forms of lung cancer.
Bayer said Phase III trials in patients with non-small cell lung cancer (NSCLC) had been stopped because Nexavar, already used to treat liver and some kidney cancers, "would not meet its primary end-point of improved overall survival."
Nexavar is one of the group's best selling treatments, while NSCLC is the most common form of lung cancer.
"While we are disappointed at this outcome ... we will continue to investigate its potential across a wide variety of tumors," Bayer said in a statement.
Shares in the German drug company fell 1.28 percent to 83.46 euros while the overall stockmarket rose nearly two percent.